Novavax Dividend

Dividend criteria checks 0/6

Novavax does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	US$0
Earnings per share	-US$13.39
Dividend yield forecast in 3Y	0%

Recent dividend updates

No updates

Recent updates

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

Mar 05

COVID-19 remains global health emergency - WHO

Oct 19

Novavax spikes ahead of presentations on COVID-19 vaccine portfolio

Oct 10

US Supreme Court declines to hear challenge of COVID vaccine mandate for health workers

Oct 03

Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimates

Aug 11

Novavax COVID-19 shot is linked to rare cases of heart inflammation – EU agency

Aug 03

Novavax gets Japanese regulatory nod for use of its COVID vaccine in teens

Jul 26

Serum Institute of India supplies Novavax's COVID vaccine in US

Jul 18

Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.

Jul 11

Novavax wins EU nod to use COVID-19 vaccine in adolescents

Jul 05

Taiwan to get 504K doses of Novavax COVID vaccine in 1st lot this week

Jun 29

Novavax seeks label expansion for COVID-19 shot in Canada

Jun 23

The Novavax Vaccine, Finally

Jun 08

Is Novavax (NASDAQ:NVAX) Using Debt In A Risky Way?

May 24

Novavax: Buying Here Will Not End Well

May 18

Novavax: Don't Catch The Falling Knives

May 07

Novavax: Management's Revenue Guidance - If It Can Be Trusted - Makes The Bull Case

Apr 21

Stability and Growth of Payments

How stable has Novavax's dividend per share been in the past?
Month	Dividend Per Share (annual)	Avg. Yield (%)
12/31/2024	-	0%
12/31/2023	-	0%

Stable Dividend: Insufficient data to determine if NVAX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NVAX's dividend payments have been increasing.

Dividend Yield vs Market

Novavax Dividend Yield vs Market

How does NVAX dividend yield compare to the market?
Segment	Dividend Yield
Company (NVAX)	n/a
Market Bottom 25% (US)	1.7%
Market Top 25% (US)	5.2%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (NVAX)	0%

Notable Dividend: Unable to evaluate NVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NVAX has not reported any payouts.

Discover strong dividend paying companies

Strong dividend paying companies in the US market.

Novavax Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

No longer forecast to breakeven

Forecast to breakeven in 2025

Novavax, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Price target decreased by 16% to US$39.33

Consensus EPS estimates upgraded to US$4.96 loss, revenue downgraded

Consensus revenue estimates decrease by 25%

Time To Worry? Analysts Just Downgraded Their Novavax, Inc. (NASDAQ:NVAX) Outlook

No longer forecast to breakeven

Price target increased by 23% to US$68.33

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Novavax, Inc. announced that it has received $6.75 million in funding from River Private Wealth

Novavax, Inc. Announces Chief Executive Officer Changes

Novavax, Inc. Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

Price target decreased to US$61.50

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. has completed a Follow-on Equity Offering in the amount of $65 million.

Novavax, Inc. Reaffirms Revenue Guidance for the Full Year 2022

Novavax, Inc. Appoints Richard J. Rodgers as Member of Its Audit Committee and as A Member of Its Compensation Committee

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Primary Series in Adolescents

No longer forecast to breakeven

Novavax, Inc. Announces the World Health Organization Issue an Updated Emergency Use Listing (EUL) for Nuvaxovid(TM) (NVX-CoV2373) COVID-19

Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

Price target decreased to US$78.17

Consensus forecasts updated

Novavax, Inc. Announces Medicines and Healthcare Products Regulatory Agency Expands Conditional Marketing Authorization for Nuvaxovid™ COVID-19 Vaccine

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Novavax, Inc. Revises Revenue Guidance for the Year 2022

Novavax, Inc. to Report Q3, 2022 Results on Nov 08, 2022

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc.'s COVID-19 Vaccine, Adjuvanted as a Booster for Adults

COVID-19 remains global health emergency - WHO

Novavax, Inc. Announces Positive Results from Phase 1/2 Clinical Trial of Its COVID-19-Influenza Combination (CIC) Vaccine Candidate

Novavax, Inc. Presents Data from the Phase 3 PREVENT-19 Trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022

Forecast breakeven date pushed back to 2023

Novavax spikes ahead of presentations on COVID-19 vaccine portfolio

US Supreme Court declines to hear challenge of COVID vaccine mandate for health workers

Novavax makes 1M doses of its COVID-19 vaccine available for use in the UK

Forecast breakeven date pushed back to 2023

Price target decreased to US$106

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax Covid-19 Vaccine as A Primary Series for Adults Aged 18 and Older

Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as A Booster for Adults Aged 18 and Older

EU clears Novavax's COVID-19 shot for use as a booster dose in adults

Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older

Novavax Nuvaxovid COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

Novavax wins EU backing for COVID-19 booster shot

Novavax, Inc. Nuvaxovid™ Covid-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

Novavax: Finding Its Niche

Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17

Novavax, Inc. announces Nuvaxovid COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as First and Second Booster for Adults

Novavax COVID vaccine gets provisional approval in New Zealand as booster shot

Novavax, Inc. Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older

Price target decreased to US$126

Novavax Q2: Time To Turn Bullish After The Massive Collapse

Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimates

Forecast breakeven date pushed back to 2023

Novavax, Inc. Is Revises Revenue Guidance for Full Year 2022

Price target decreased to US$126

Novavax, Inc. Initiates Phase 2b/3 Hummingbird Global Clinical Trial for the Novavax Covid-19 Vaccine in Children Aged Six Months Through 11 Years

Novavax COVID-19 shot is linked to rare cases of heart inflammation – EU agency

Novavax, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

Novavax gets Japanese regulatory nod for use of its COVID vaccine in teens

Serum Institute of India supplies Novavax's COVID vaccine in US

U.S. FDA Grants Emergency Use Authorization for Novavax, Inc. COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.

Novavax, Inc. Announces European Commission Approves Expanded Conditional Marketing Authorization of Nuvaxovid™ (NVX-CoV2373) COVID-19 Vaccine in European Union for Adolescents Aged 12 Through 17

Novavax wins EU nod to use COVID-19 vaccine in adolescents

Novavax, Inc. Presents Data At FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants

Taiwan to get 504K doses of Novavax COVID vaccine in 1st lot this week

Novavax' Nuvaxovid Covid-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and over

Novavax, Inc. Covid-19 Vaccine Nuvaxovid™ Recommends for Expanded Conditional Marketing Authorization in the European Union by Chmp for Adolescents Aged 12 Through 17

Novavax seeks label expansion for COVID-19 shot in Canada